Share your perspective and help improve the health of our community! We are conducting a Community Health Needs Assessment (CHNA) to help us better understand the health needs of the community our health system serves. Learn more and take the short survey.
Discontinuation of In-House Rotavirus Antigen, Fecal Leukocyte Lactoferrin, and aPTT Mixing Studies
DESCRIPTION: Effective Jan. 6, 2026, the VMC Laboratory will discontinue in-house testing for Rotavirus Antigen, Fecal Leukocyte Lactoferrin, and aPTT mixing studies. These assays will now be performed by LabCorp. The aPTT assay will continue to be performed in-house; however, abnormal results will no longer reflex to a mixing study.
WHY: The utilization of Rotavirus and Lactoferrin testing has declined significantly. Additionally, aPTT with reflex to mixing study is intended for outpatient populations and is not indicated for inpatient testing.
TEST NAME/CODE:
|
Test Name |
Order Code |
Performing Laboratory |
Notes on use |
|
Fecal Leukocyte Lactoferrin (Quantitative) |
LAB731 |
LabCorp |
TAT: 4-8 days |
|
Rotavirus Antigen, Stool |
LAB443 |
LabCorp |
TAT: 1-4 days |
|
Activated Partial Thromboplastin Time (aPTT) w/ Mixing Study |
LAB326 |
LabCorp |
TAT: 2-3 days Intended for outpatient use. |
|
Activated Partial Thromboplastin Time (aPTT) |
LAB325 No change to test code |
VMC |
SPECIMEN REQUIREMENTS: No change in specimen requirements.
ACTION:
- Clinicians and staff should review available testing and ensure appropriate test selection based on clinical needs.
- Clinicians may need to add the new test as a favorite on preference lists.
EFFECTIVE DATE: January 6, 2026
CONTACT: For questions or additional information, please reach out to:
- Christina Kwong, MD, PhD. – VMC Lab Medical Director| christina_kwong@valleymed.org
- Albert Cabrera – Lab Director | albert_cabrera@valleymed.org
- Michaela Suess – Lab Ops & Quality Manager | Michaela_suess@valleymed.org